Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 2Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Lymphoma, Non-Hodgkin 1Fanconi Anemia 1Colorectal Neoplasms 1Anus Neoplasms 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × SRA737 × Gastrointestinal × Clear all
NCT02797964 2023-06-18

A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer

Sierra Oncology LLC - a GSK company

Phase 1/2 Completed
107 enrolled 20 charts
Classical hematologyGastrointestinalHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Fanconi Anemia, Lymphoma, Non-Hodgkin, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡